Without Graphite, There Would Be ZERO EV Batteries!
Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.
See This Special Report to Get the Full Story
Bonnie L. Bassler net worth and biography

Bonnie Bassler Biography and Net Worth

Bonnie L. Bassler, PhD, joined the board in 2016. She is currently the Chair of the Department of Molecular Biology and the Squibb Professor in Molecular Biology at Princeton University, and a Howard Hughes Medical Institute Investigator. Dr. Bassler has previously served as the President of the American Society for Microbiology, as well as on the boards for the American Association for the Advancement of Science, the National Science Foundation and the American Academy of Microbiology. She has been elected to the National Academy of Sciences, the American Academy of Arts and Sciences, the Royal Society and the American Philosophical Society and has received many scientific honors, including a MacArthur Foundation Fellowship, the Lounsbery Award and the Shaw Prize for Life Science and Medicine. Dr. Bassler received her BSc from the University of California, Davis, and her PhD in Biochemistry from Johns Hopkins University. She served as a Postdoctoral Fellow and Research Scientist at the Agouron Institute in La Jolla, CA, before becoming a faculty member at Princeton University. Dr. Bassler served as a director of Sanofi from November 2014 to July 2016 and currently serves on the board of directors of Kaleido Biosciences, Inc.

What is Bonnie L. Bassler's net worth?

The estimated net worth of Bonnie L. Bassler is at least $813,339.40 as of September 9th, 2022. Ms. Bassler owns 1,082 shares of Regeneron Pharmaceuticals stock worth more than $813,339 as of December 1st. This net worth evaluation does not reflect any other investments that Ms. Bassler may own. Learn More about Bonnie L. Bassler's net worth.

How do I contact Bonnie L. Bassler?

The corporate mailing address for Ms. Bassler and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at [email protected] Learn More on Bonnie L. Bassler's contact information.

Has Bonnie L. Bassler been buying or selling shares of Regeneron Pharmaceuticals?

Bonnie L. Bassler has not been actively trading shares of Regeneron Pharmaceuticals within the last three months. Most recently, Bonnie L. Bassler sold 609 shares of the business's stock in a transaction on Friday, September 9th. The shares were sold at an average price of $741.00, for a transaction totalling $451,269.00. Following the completion of the sale, the director now directly owns 1,082 shares of the company's stock, valued at $801,762. Learn More on Bonnie L. Bassler's trading history.

Who are Regeneron Pharmaceuticals' active insiders?

Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Regeneron Pharmaceuticals?

In the last year, insiders at the biopharmaceutical company sold shares 44 times. They sold a total of 142,306 shares worth more than $94,657,219.74. The most recent insider tranaction occured on November, 23rd when EVP Plew Daniel P Van sold 11,972 shares worth more than $8,868,259.00. Insiders at Regeneron Pharmaceuticals own 9.0 % of the company. Learn More about insider trades at Regeneron Pharmaceuticals.

Information on this page was last updated on 11/23/2022.

Bonnie L. Bassler Insider Trading History at Regeneron Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/9/2022Sell609$741.00$451,269.001,082View SEC Filing Icon  
4/7/2022Sell1,240$725.00$899,000.001,082View SEC Filing Icon  
8/5/2021Sell2,559$600.00$1,535,400.003,450View SEC Filing Icon  
6/19/2020Sell2,559$630.02$1,612,221.183,202View SEC Filing Icon  
6/5/2020Sell2,559$600.00$1,535,400.003,202View SEC Filing Icon  
See Full Table

Bonnie L. Bassler Buying and Selling Activity at Regeneron Pharmaceuticals

This chart shows Bonnie L Bassler's buying and selling at Regeneron Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals logo
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Read More

Today's Range

Now: $755.08
Low: $752.48
High: $760.38

50 Day Range

MA: $729.67
Low: $684.63
High: $759.91

2 Week Range

Now: $755.08
Low: $538.01
High: $769.63

Volume

3,797 shs

Average Volume

603,726 shs

Market Capitalization

$82.23 billion

P/E Ratio

15.92

Dividend Yield

N/A

Beta

0.2